Changes in plasma cytokines after treatment of ascaris lumbricoides infection in individuals with HIV-1 infection.
Albendazole treatment of individuals with human immunodeficiency virus type 1 (HIV-1) and Ascaris lumbricoides co-infection has led to significantly improved CD4(+) cell counts and a trend for lower plasma HIV-1 RNA levels in a previous randomized placebo-controlled trial. To define mechanisms by which deworming contributed to changes in markers of HIV-1 disease progression, plasma cytokine levels were evaluated. Albendazole treatment, compared with placebo, was associated with significantly decreased plasma interleukin (IL) 10 levels (P = .01)ot associated with significant changes in levels of IL-1beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-12p70, IL-13, interferon gamma, tumor necrosis factor alpha, or thymic stromal lymphopoietin. Treatment of A. lumbricoides co-infection may delay HIV-1 disease progression by reducing helminth-induced, IL-10-mediated immunosuppression.
Blish
Catherine A
CA
Division of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98104, USA.
Sangaré
Laura
L
Herrin
Bradley R
BR
Richardson
Barbra A
BA
John-Stewart
Grace
G
Walson
Judd L
JL
D000328:Adult; D015766:Albendazole / Q000627:therapeutic use; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use; D001196:Ascariasis / Q000188:drug therapy* / Q000276:immunology*; D017164:Ascaris lumbricoides / Q000276:immunology*; D016207:Cytokines / Q000097:blood*; D015658:HIV Infections / Q000150:complications* / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D010919:Placebos / Q000008:administration & dosage; D055815:Young Adult
D000871:Anthelmintics; D016207:Cytokines; D010919:Placebos; D015766:Albendazole